Fucoxanthin · Evidence-First Fact Sheet
Fucoxanthin is an allenic xanthophyll carotenoid from brown seaweed and marine microalgae with rct-supported evidence for supporting healthy markers of metabolic syndrome, body weight, liver health, and glucose metabolism.
Quick Summary
Fucoxanthin is an allenic xanthophyll carotenoid concentrated in edible brown seaweeds (kelp · wakame · hijiki) and certain marine microalgae such as Phaeodactylum tricornutum. Randomized controlled trials support a role for fucoxanthin in supporting healthy body weight, waist circumference, and blood pressure in adults with metabolic syndrome; in supporting healthy glucose markers including HbA1c at oral doses as low as 2 mg/day; and in supporting liver health markers in adults with non-alcoholic fatty liver disease — though the strongest of these signals come from complex formulations rather than standalone fucoxanthin. Cognitive evidence is preliminary with mixed long-term findings. Oral fucoxanthin is generally well tolerated at clinical doses up to 12 mg/day, with a 60 mg/day human safety study showing no significant adverse events. Pregnant, lactating, and pediatric populations should consult a healthcare provider before use.
Overview · What is Fucoxanthin?
Fucoxanthin (CAS 3351-86-8 · molecular formula C₄₂H₅₈O₆ · PubChem CID 5281239) is an orange-brown xanthophyll carotenoid distinguished by an uncommon allenic bond (C=C=C), a 5,6-epoxide group, an acetyloxy group, and two hydroxyl groups arranged across a long polyene backbone. This unusual chemistry sets fucoxanthin apart from more familiar dietary carotenoids such as β-carotene and astaxanthin, and is associated with a unique thermogenic mechanism in adipose tissue (see §3).
Natural sources are almost exclusively marine. The highest-concentration commercial sources are edible brown seaweeds (Laminaria · Undaria pinnatifida (wakame) · Sargassum (hijiki)) and cultivated marine microalgae such as Phaeodactylum tricornutum. After ingestion, fucoxanthin is hydrolyzed and metabolized in the gut and liver primarily to fucoxanthinol, which is considered the principal bioactive metabolite circulating in plasma and reaching adipose tissue.
ASXAN Group develops fucoxanthin as a strategic carotenoid alongside astaxanthin, leveraging a shared synthetic-biology platform: a Yarrowia lipolytica yeast fermentation route and a Phaeodactylum tricornutum microalgal cultivation route, supporting batch consistency and well-characterized composition profiles. ASXAN's regulatory roadmap covers Japan (FFC pathway), Korea, the United States (NDI), and the European Union (Novel Food re-application strategy). This page is part of ASXAN's evidence-first educational hub and does not constitute a purchase recommendation.
Mechanism of Action
Fucoxanthin's bioactivity arises from a small set of interconnected mechanisms, of which one — UCP1 upregulation in white adipose tissue — is particularly distinctive. Based on preclinical and mechanistic studies, the following pathways are proposed:
UCP1 upregulation and white adipose tissue "browning." This is the most differentiated mechanism attributed to fucoxanthin. The principal circulating metabolite fucoxanthinol is reported to upregulate mitochondrial uncoupling protein 1 (UCP1) expression in white adipose tissue (WAT). UCP1 dissipates the mitochondrial proton gradient as heat rather than synthesizing ATP, a phenomenon usually confined to brown adipose tissue. Induction of UCP1 in WAT — informally described as "browning" — is associated with increased thermogenesis, increased fatty-acid oxidation, and increased basal metabolic rate in animal models. Direct human evidence is limited to indirect signals via UCP1 genotype interaction in clinical trials (see §4.4).
PPAR-γ modulation and adipocyte / hepatic lipid metabolism. Fucoxanthin is proposed to modulate PPAR-γ signaling in adipocytes, influencing adipocyte differentiation, lipid droplet formation, and adiponectin secretion — pathways relevant to insulin sensitivity and to hepatic lipid handling in non-alcoholic fatty liver disease (NAFLD).
AMPK activation. AMP-activated protein kinase (AMPK) activation in hepatocytes is reported to suppress SREBP-1c and reduce de novo hepatic lipogenesis while promoting fatty-acid β-oxidation. The mechanistic evidence comes principally from animal NAFLD models.
NRF2 / Keap1 pathway activation (shared with astaxanthin). Fucoxanthin is proposed to induce conformational change of Keap1, releasing NRF2 for nuclear translocation and upregulating phase II detoxification enzymes (HO-1 · NQO1 · GCL). This is the same endogenous antioxidant pathway documented for astaxanthin and other dietary carotenoids — see the astaxanthin fact sheet for a deeper discussion.
NF-κB signaling inhibition (shared with astaxanthin). Suppression of IκBα degradation reduces p65 nuclear translocation and downregulates pro-inflammatory mediators including IL-6, TNF-α, and NLRP3 — dampening chronic low-grade inflammation. Mechanistic evidence is extensive at the preclinical level; direct human inflammatory-endpoint trials of standalone oral fucoxanthin are limited.
Direct singlet oxygen and peroxyl radical scavenging. The allenic bond, epoxide, and conjugated polyene system contribute direct antioxidant activity, though in vitro singlet-oxygen quenching is generally weaker than astaxanthin's (which carries an unusually long 11-conjugated-double-bond backbone).
These mechanisms together describe fucoxanthin not as a targeted pharmacologic agent but as a dietary modulator of adipose thermogenesis, hepatic lipid handling, and oxidative-stress / inflammation network homeostasis. Direct human mechanistic evidence is limited — particularly for the UCP1-WAT browning pathway, which has been demonstrated in animal models but only indirectly inferred in humans via UCP1 genotype-dependent trial responses. Mechanism narratives below should be interpreted accordingly.
References: PMID 28620480 (UCP1 genotype interaction · Mikami 2017), PMID 33809062 (NAFLD mechanism discussion · Shih 2021).
Evidence-Based Benefits
Each benefit below opens with an evidence tier label following NIH-ODS conventions: meta-analysis-supported > rct-supported > emerging > preclinical-major. Effect sizes, sample sizes, and study designs are reported as published — no values are inferred. Where the source intervention is a multi-ingredient formulation, this is explicitly flagged with [complex formulation] to prevent over-attribution to standalone fucoxanthin.
Metabolic Syndrome Composite Markers
Evidence Tier: rct-supported
A 2023 double-blind placebo-controlled randomized controlled trial (López-Ramos et al.) evaluated standalone fucoxanthin at 12 mg/day for 12 weeks in 28 adults with metabolic syndrome. Versus placebo, the fucoxanthin arm showed significant reductions in body mass index, body weight, waist circumference, systolic and diastolic blood pressure, triglycerides, and total insulin secretion. No serious adverse events were reported. This is one of only two head-to-head standalone-fucoxanthin oral RCTs identified in the current literature search (the other is Mikami 2017, see §4.4).
These data support fucoxanthin's role in supporting healthy markers of metabolic syndrome — body weight, central adiposity, blood pressure, and triglycerides — in adults with established metabolic risk. They do not establish fucoxanthin as a treatment for metabolic syndrome, hypertension, or hypertriglyceridemia, which are clinical diagnoses requiring medical management.
References: PMID 37405785 (López-Ramos A et al. 2023, Journal of Medicinal Food).
Body Weight and Body Fat Management
Evidence Tier: rct-supported [complex formulation]
A 2010 double-blind placebo-controlled RCT (Abidov et al., n=151) evaluated Xanthigen™ — a complex formulation containing fucoxanthin and pomegranate seed oil — at a dose providing 2.4 mg fucoxanthin per day for 16 weeks in obese premenopausal women with non-alcoholic fatty liver disease (NAFLD) or with normal liver fat. Versus placebo, the Xanthigen arm showed a 5.5 kg reduction in body weight, a 3.5 kg reduction in body fat mass, an increase in resting metabolic rate, and (within the NAFLD subgroup) reductions in liver fat and liver enzymes.
These findings are commonly cited as evidence for fucoxanthin's weight-management role. It is important to note that the active intervention was a fucoxanthin + pomegranate seed oil formulation, not isolated fucoxanthin; the contribution of each component cannot be separated from this trial alone. A standalone fucoxanthin reference exists in López-Ramos 2023 (§4.1), which reports body weight and BMI reductions at 12 mg/day over 12 weeks in a smaller (n=28) metabolic syndrome population.
These data support a role for fucoxanthin-containing formulations in supporting body weight management as part of a healthy lifestyle. Fucoxanthin should not be characterized as a "fat burner," "weight-loss miracle," or "metabolism booster"; obesity is a clinical condition (ICD-10 E66) requiring lifestyle, dietary, and where appropriate medical management. Consult a healthcare provider before starting any weight management regimen.
References: PMID 19840063 (Abidov M et al. 2010, Diabetes, Obesity and Metabolism · Xanthigen complex formulation), PMID 37405785 (López-Ramos A et al. 2023, standalone).
Liver Health Markers in NAFLD Populations
Evidence Tier: rct-supported [complex formulation]
Educational notice: Non-alcoholic fatty liver disease (NAFLD, ICD-10 K76.0) is a clinical diagnosis requiring medical evaluation and management. The studies below evaluate fucoxanthin- or fucoxanthin-containing formulations' effects on specific liver, lipid, and glycemic biomarkers in research settings; they do not establish fucoxanthin as a treatment for NAFLD. Individuals with NAFLD should consult their hepatologist or primary care provider before adding any supplement to their care plan.
A 2021 double-blind placebo-controlled RCT (Shih et al., n=42 adults with NAFLD) evaluated LMF-HSFx — a complex formulation containing low-molecular-weight fucoidan complexed with high-stability fucoxanthin — for 24 weeks. Versus placebo, the active arm showed significant reductions in alanine aminotransferase (ALT), aspartate aminotransferase (AST), total cholesterol, triglycerides, fasting blood glucose, and HbA1c, alongside improvements across four mechanistic domains: hepatic steatosis, inflammation, fibrosis, and insulin resistance.
The Abidov 2010 trial (§4.2) also reported reductions in liver fat and liver enzymes within its NAFLD subgroup, using the Xanthigen complex formulation containing fucoxanthin and pomegranate seed oil.
These data support a role for fucoxanthin-containing complex formulations in supporting liver health markers in adults with metabolic syndrome and NAFLD. Two important caveats apply: (i) both pivotal trials used complex formulations rather than standalone fucoxanthin — the relative contribution of fucoidan, pomegranate seed oil, and fucoxanthin cannot be separated within these designs; and (ii) the European Food Safety Authority (EFSA) declined a 2023 Novel Food application for a Phaeodactylum tricornutum ethanolic extract on grounds of process consistency, compositional information, and pheophorbide A safety considerations — not on grounds of the trial efficacy data themselves. This regulatory position underscores the importance of source consistency and well-characterized composition in any liver-related fucoxanthin research narrative. Consult a healthcare provider before using any supplement for liver-related concerns.
References: PMID 33809062 (Shih PH et al. 2021, Marine Drugs · LMF-HSFx complex formulation), PMID 19840063 (Abidov 2010 NAFLD subgroup).
Healthy Glucose Markers and UCP1 Genotype Interaction
Evidence Tier: rct-supported
Educational notice: Type 2 diabetes mellitus (T2DM, ICD-10 E11) is a clinical diagnosis requiring medical management. The studies below evaluate fucoxanthin's effects on glycemic biomarkers — including HbA1c, fasting glucose, and insulin sensitivity — in research populations; they do not establish fucoxanthin as a treatment for T2DM, prediabetes, or insulin resistance. Individuals with diagnosed glucose disorders should not modify their treatment regimen without consulting their healthcare provider.
A 2017 three-arm randomized controlled trial (Mikami et al., n=60 normal-weight and obese Japanese adults) compared 0, 1, and 2 mg/day of fucoxanthin (delivered in fucoxanthin-enriched akamoku oil) for 8 weeks. The 2 mg/day arm showed a significant reduction in HbA1c versus the 0 mg/day arm — notably, this is a standalone fucoxanthin signal at one of the lowest oral doses in the clinical literature. Visceral fat change between groups was not statistically significant. A subgroup analysis suggested the HbA1c response was more pronounced in carriers of the UCP1-3826 G/G genotype, consistent with the proposed UCP1-mediated mechanism (§3).
The Shih 2021 LMF-HSFx trial in NAFLD (§4.3) and the López-Ramos 2023 metabolic syndrome trial (§4.1) also reported reductions in glycemic markers — HbA1c, fasting blood glucose, or insulin secretion — supporting a consistent direction of effect across populations.
These data support fucoxanthin's role in supporting healthy glucose metabolism in adults with metabolic markers above the normal range — particularly at low to moderate doses (2–12 mg/day) over 8–24 weeks. The strongest standalone-fucoxanthin signal (Mikami 2017) is preliminary and warrants replication in larger, multi-ethnic populations.
References: PMID 28620480 (Mikami N et al. 2017, Journal of Nutritional Science), PMID 33809062 (Shih 2021), PMID 37405785 (López-Ramos 2023).
Cognitive Function · Preliminary and Mixed
Evidence Tier: emerging
Fucoxanthin's cognitive evidence base is preliminary and characterized by mixed signals between short-term and longer follow-up trials. Both pivotal studies used a Phaeodactylum tricornutum microalgal extract — not isolated fucoxanthin — so findings are best described as evidence for the microalgal extract rather than for fucoxanthin alone.
A 2024 double-blind placebo-controlled parallel-arm RCT (Yoo et al., n=43 adults aged 64.3 ± 6.0 with self-perceived cognitive decline) evaluated 1100 mg/day of Phaeodactylum tricornutum extract delivering 8.8 mg/day fucoxanthin for 12 weeks. Versus placebo, the active arm showed improvements across working and secondary memory, vigilance, attention, executive function, reaction time, and accuracy. No serious adverse events were reported.
A 2025 trial published in Frontiers in Aging (n=66 adults aged 55–75 with age-associated memory impairment) evaluated a lower dose — 550 mg/day of Phaeodactylum tricornutum extract delivering 4.4 mg/day fucoxanthin — for 24 weeks. The primary cognitive endpoint and most other cognitive parameters showed no statistically significant between-group difference at either 12 or 24 weeks. Within-group analyses at 24 weeks did suggest improvements on Stroop reaction time and delayed word-recall scores, alongside reductions in high-sensitivity CRP and improvements in perceived stress and mood; however, between-group comparisons remained non-significant.
Preliminary findings suggest that Phaeodactylum tricornutum microalgal extract containing fucoxanthin may support certain cognitive domains in older adults with self-perceived cognitive decline; longer follow-up evidence is mixed and does not currently support a between-group cognitive benefit. These data do not support a "cognitive enhancement" framing or a treatment effect on age-related cognitive impairment or dementia.
References: PMID 39275314 (Yoo C et al. 2024, Nutrients), Frontiers in Aging 2025 (DOI 10.3389/fragi.2025.1540115 · PMC12075122).
Dosage
Most clinical evidence for fucoxanthin uses oral doses in the range of 1–12 mg/day, taken with a fat-containing meal to support absorption (fucoxanthin is highly lipophilic and has relatively low intrinsic bioavailability).
Typical dose ranges by use case, based on published RCT data:
| Direction | Validated dose | Typical onset | Source |
|---|---|---|---|
| Healthy body weight / body fat (complex formulation) | 2.4 mg/day complex formulation | 16 weeks | Abidov 2010 (Xanthigen) |
| Metabolic syndrome composite (standalone) | 12 mg/day | 12 weeks | López-Ramos 2023 |
| Healthy glucose markers / HbA1c (standalone) | 2 mg/day | 8 weeks | Mikami 2017 |
| Liver health markers in NAFLD (complex formulation) | 2.4 mg/day complex formulation | 16–24 weeks | Abidov 2010 · Shih 2021 |
| Cognitive function (microalgal extract) | 4.4–8.8 mg/day | 12–24 weeks | Yoo 2024 · Frontiers in Aging 2025 |
Regulatory framework.
- United States (FDA). A New Dietary Ingredient (NDI) notification (Algatech FucoVital) supports 3 mg/day with no time limit and 5 mg/day for up to 90 days. Other dose levels fall outside the scope of this NDI and would require separate notification.
- Japan. No FOSHU-specific approval; the Foods with Function Claims (FFC, 2015) notification pathway is available. Brown seaweed (wakame · kombu · hijiki) carries a long history of dietary use.
- European Union (EFSA). A 2023 Novel Food application for a Phaeodactylum tricornutum ethanolic extract at 437 mg/day was declined on grounds of process consistency, compositional information, and the potential presence of pheophorbide A — not on grounds of efficacy. As of this writing, there is no independent EU Novel Food authorization for purified fucoxanthin; re-application with improved process controls and composition data is the recognized pathway.
- China (NMPA). Purified fucoxanthin is not currently listed in the New Food Raw Material catalog. Brown seaweed remains a traditional food; standalone purified fucoxanthin requires additional regulatory review.
- Brazil (ANVISA). Not currently listed in the approved bioactive substances inventory; a Novel Food application would likely be required.
Individual response varies. Consult a healthcare provider for personalized dosage, particularly if you take medication or have a chronic condition.
Safety and Drug Interactions
Fucoxanthin's safety profile is well characterized at the preclinical level and at clinical doses up to 60 mg/day in short-term human studies, though long-term (>24 weeks) human safety data are limited.
Preclinical safety. A No Observed Adverse Effect Level (NOAEL) above 200 mg/kg body weight/day has been established in a 30-day repeated-dose study in mice; a single 2,000 mg/kg dose produced no mortality. A 13-week subchronic toxicity study in rats supports dietary supplementation use.
Highest-dose human evidence. A 2017 open-label safety study (Hashimoto et al., Food & Function) reported that 60 mg/day for 4 weeks in healthy adults produced no significant adverse events. At 20 mg/day for 4 weeks, hematology and hepatic / renal function parameters showed no changes; approximately 5% of participants reported mild gastrointestinal discomfort (loose stool · soft stool · abdominal bloating) at doses ≥10 mg/day, with adaptation over time.
Provisional intake reference. EFSA's provisional Acceptable Daily Intake is 0.5 mg/kg body weight/day (approximately 34 mg/day for a 68 kg adult). The 2023 EFSA Novel Food rejection (see §5) was based on process and compositional concerns, not on a toxicological adverse-effect finding.
Adverse events. The most commonly reported observations are mild, reversible gastrointestinal discomfort at doses ≥10 mg/day, with adaptation reported over time. One animal study observed an increase in total cholesterol across dose arms in mice; this signal has not been replicated in human trials to date.
Drug interactions. No clinically significant drug interactions are currently established. Theoretical additive effects with antihyperglycemic medications (metformin · sulfonylureas · GLP-1 receptor agonists) and antihypertensive medications have been raised based on the SBP / DBP / HbA1c / triglyceride improvements reported in the metabolic syndrome and NAFLD RCTs cited in §4; head-to-head clinical interaction data are lacking. Individuals taking antihyperglycemic or antihypertensive prescriptions should consult their prescribing clinician before adding fucoxanthin.
Special populations. No dedicated safety data exist for pregnancy or lactation; consultation with a healthcare provider is recommended. Pediatric safety data are also limited. Crustacean allergy is not a relevant concern for marine-algal or microalgal fucoxanthin sources (as opposed to krill-derived ingredients). Long-term (>24 weeks) human safety data are currently lacking and represent a recognized gap in the evidence base.
References: Hashimoto et al. 2017 (Food & Function · 60 mg/day safety), PMID 19797858 (Beppu F et al. 2009 · mouse NOAEL), PMID 21720124 (Iio K et al. 2011 · rat 13-week subchronic).
ASXAN Sources
ASXAN Group develops fucoxanthin as a strategic carotenoid alongside astaxanthin, leveraging a shared synthetic-biology platform with two complementary production routes: a Yarrowia lipolytica yeast fermentation route, and a Phaeodactylum tricornutum marine microalgal cultivation route. Both routes are designed to deliver batch-consistent, well-characterized composition profiles — a feature explicitly relevant to the regulatory pathway identified in §5 (where compositional consistency and pheophorbide A control are recognized prerequisites for EU Novel Food authorization). The regulatory roadmap covers Japan (FFC pathway), Korea, the United States (NDI), and the European Union (Novel Food re-application). This educational hub does not sell finished consumer products.
References
All PMIDs verified by cross-source PubMed search on 2026-05-23. Effect sizes are reported as published.
Metabolic Syndrome Composite (§4.1)
- PMID 37405785 · López-Ramos A, González-Ortiz M, Martínez-Abundis E, Pérez-Rubio KG (2023) · "Effect of Fucoxanthin on Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion" · Journal of Medicinal Food
Body Weight and Body Fat (§4.2)
- PMID 19840063 · Abidov M et al. (2010) · "The effects of Xanthigen™ in the weight management of obese premenopausal women with non-alcoholic fatty liver disease and normal liver fat" · Diabetes, Obesity and Metabolism · Xanthigen
[complex formulation: fucoxanthin + pomegranate seed oil]
Liver Health Markers in NAFLD (§4.3)
- PMID 33809062 · Shih PH et al. (2021) · "Fucoidan and Fucoxanthin Attenuate Hepatic Steatosis and Inflammation of NAFLD through Modulation of Leptin/Adiponectin Axis" · Marine Drugs · LMF-HSFx
[complex formulation: low-molecular-weight fucoidan + high-stability fucoxanthin]
Glycemic Markers and UCP1 Genotype (§4.4)
- PMID 28620480 · Mikami N et al. (2017) · "Reduction of HbA1c levels by fucoxanthin-enriched akamoku oil possibly involves the thrifty allele of uncoupling protein 1 (UCP1): a randomised controlled trial in normal-weight and obese Japanese adults" · Journal of Nutritional Science
Cognitive Function (§4.5)
- PMID 39275314 · Yoo C et al. (2024) · "Effects of Supplementation with a Microalgae Extract from Phaeodactylum tricornutum Containing Fucoxanthin on Cognition and Markers of Health in Older Individuals with Perceptions of Cognitive Decline" · Nutrients
- Frontiers in Aging (2025) · "Promising benefits of six-month Phaeodactylum tricornutum microalgae supplementation on cognitive function and inflammation in healthy older adults with age-associated memory impairment" · DOI 10.3389/fragi.2025.1540115 · PMC12075122 · ⚠️ Primary endpoint between-group non-significant
Topical (Negative for Oral) (§4.6)
- PMID 32271708 · Kang HW et al. (2020) · Fucoxanthin antiaging cream RCT · Marine Drugs · ⚠️ Topical formulation only — does not extend to oral supplementation
Safety (§6)
- Food & Function (2017) · Hashimoto et al. · Fucoxanthin safety study · healthy adults · 60 mg/day × 4 weeks · no significant adverse events
Supporting preclinical safety: PMID 19797858 (Beppu F et al. 2009 · mouse NOAEL >200 mg/kg bw/day) · PMID 21720124 (Iio K et al. 2011 · rat 13-week subchronic).
Regulatory reference (not a citation): EFSA Journal 2023; 21(7):8072 · "Safety of an ethanolic extract of the dried biomass of the microalga Phaeodactylum tricornutum as a novel food" · DOI 10.2903/j.efsa.2023.8072.